Clinical observation of herombopag combined with recombinant human thrombopoietin in the treatment of primary immune thrombocytopenia / 中国药房

OBJECTIVE To investigate the clinical efficacy and safety of herombopag combined with recombinant human thrombopoietin （rhTPO） in the treatment of primary immune thrombocytopenia （ITP） in the real world. METHODS A retrospective study was conducted on the patients diagnosed with ITP in the Second Affiliated Hospital of Bengbu Medical College from January 2021 to December 2022. Among them， 98 patients who were treated with a combination of herombopag and rhTPO were included in the observation group， and 157 patients who were treated with rhTPO alone were included in the control group. The changes in platelet count， clinical efficacy， bleeding， platelet transfusion rate and adverse drug reactions before and after treatment were observed and compared between the two groups. RESULTS Since the 8th day of treatment， there was a statistically significant difference in platelet count between the two groups （[ 61.04±13.46）×109 L－1 in observation group， （52.11±12.06）× 109 L－1 in control group] （P＜0.05）， and there also was a statistically significant difference in the peak and stable values of platelet count between the two groups （P＜0.05）. The total effective rates of the observation group and the control group were 79.59% and 66.88%， with cumulative response rates of 81.32% and 68.68%， and median response durations of 8 days and 10 days， respectively； these differences were statistically significant （P＜0.05）. During the treatment period， the bleeding rates of the observation group and control group were 3.06% and 8.28% （P＜0.05）， bleeding events were categorized as grade 1 or 2， and platelet transfusion rates were 31.63% and 40.76%； the differences in bleeding rates and platelet transfusion rates between the two groups was statistically significant （P＜0.05）. The incidences of adverse drug reactions in the two groups were 11.22% and 9.55%， respectively， with no statistically significant difference （P＞0.05）， and no moderate to severe adverse drug reaction was found. CONCLUSIONS The combination of herombopag and rhTPO can significantly increase platelet levels and response rate， and reduce bleeding rate and platelet transfusion rate in ITP patients， with good safety.

Relationship between the Expression of miRNA181a-5p and the Imbalance of Treg/Th17 in Primary Immune Thrombocytopenia / 中国实验血液学杂志

OBJECTIVE@#To investigate the role of relationship between the expression of miRNA181a-5p and imbalance of Treg/Th17 in the pathogenesis of primary immune thrombocytopenia(ITP), which contributes to clarify the mechanism of T cell immune imbalance in ITP patients.@*METHODS@#Peripheral blood was collected from 37 ITP patients, concluding 21 untreated patients and 16 effectively treated patients, and 19 healthy controls; Peripheral blood mononuclear cells (PBMC) were isolated and the expression of miRNA181a-5p and Notch1 was analyzed by RT-PCR. The proportion of Th17 subsets and Treg cells in the peripheral circulation was detected by flow cytometer (FCM). Clinical data of ITP group was collected, including age, platelet count and disease course.@*RESULTS@#The expression of miR-181a-5p was significantly decreased in ITP group than that of healthy control group (P＜0.01). After effective treatment, the expression of miR-181a-5p was significantly higher than that of ITP group (P＜0.05), but still significantly lower than that of healthy control group (P＜0.01); The expression of Notch1 was significantly increased in ITP group and effectively treated group than that of healthy control group (P＜0.01). There was no significant difference in proportion of Treg cells in ITP group, effectively treated group and healthy control group (P＞0.05). The proportion of Th17 subsets in ITP group was significantly increased than that of healthy control group (P＜0.05), while the ratio of Treg/Th17 was significantly decreased (P＜0.05). There was a positive correlation between the expression of miR-181a-5p and ratio of Treg/Th17 in ITP group (r=0.555).@*CONCLUSION@#The expression of miR-181a-5p is significantly decreased in ITP patients, which is closely related to the imbalance of Treg/Th17 cells. After effective treatment, the expression of miR-181a-5p can be significantly corrected, but still failed to reach the level of healthy people. While the expression of Notch1 is significantly increased in ITP patients, and could not reach the level of healthy people after effective treatment.

Expression of miR-106b-5p in children with primary immune thrombocytopenia and its correlation with T cells / 中国当代儿科杂志

OBJECTIVES@#To study the expression level of plasma miR-106b-5p in primary immune thrombocytopenia (ITP) and its correlation with the levels of T helper 17 cell (Th17) and regulatory T cell (Treg) and the Th17/Treg ratio.@*METHODS@#A total of 79 children with ITP (ITP group) and 40 healthy children (control group) were selected as subjects. According to the treatment response, the 79 children with ITP were divided into three groups: complete response (n=40), partial response (n=18), and non-response (n=21). Quantitative real-time PCR was used to measure the expression level of miR-106b-5p. Flow cytometry was used to measure the frequencies of Th17 and Treg, and the Th17/Treg ratio was calculated. The correlation of the expression level of plasma miR-106b-5p with the frequencies of Th17 and Treg and the Th17/Treg ratio was analyzed.@*RESULTS@#Compared with the control group, the ITP group had significantly higher levels of miR-106b-5p, Th17, and Th17/Treg ratio (P<0.05) and a significantly lower level of Treg (P<0.05). After treatment, the ITP group had significant reductions in the levels of miR-106b-5p, Th17, and Th17/Treg ratio (P<0.05) and a significant increase in the level of Treg (P<0.05). Compared with the partial response and non-response groups, the complete response group had significantly lower levels of miR-106b-5p, Th17, and Th17/Treg ratio (P<0.05) and a significantly higher level of Treg (P<0.05). The correlation analysis showed that in the children with ITP, the expression level of plasma miR-106b-5p was positively correlated with the Th17 level and the Th17/Treg ratio (r=0.730 and 0.816 respectively; P<0.001) and was negatively correlated with the Treg level (r=-0.774, P<0.001).@*CONCLUSIONS@#A higher expression level of miR-106b-5p and Th17/Treg imbalance may be observed in children with ITP. The measurement of miR-106b-5p, Th17, Treg, and Th17/Treg ratio during treatment may be useful to the evaluation of treatment outcome in children with ITP.

Cost-utility analysis of Recombinant human thrombopoietin injection and Etrapopa ethanolamine tablets in the second-line treatment of primary immune thrombocytopenia / 中国药房

OBJECTIVE To evaluate the econo mical efficiency of Recombinant human thrombopoietin injection （called “rhTPO”for short ）versus Etrapopa ethanolamine tablets （called“Etrapopa”for short ）in the second-line treatment of primary immune thrombocytopenia （ITP）in the Chinese adult patients. METHODS Based on the decision tree-embedded Markov model with a 4-week cycle ，the cost and utility related to bleeding events and adverse events after the use of the two drugs were measured and compared from the perspective of Chinese health system. The horizon was 12 weeks，and the cost and health outcome were not discounted. RESULTS Compared with Etrapopa ，rhTPO improved the quality adjusted life year by 0.002 5 and reduced the cost by 1 824.36 yuan，which was the absolute advantage scheme. Univariate sensitivity analysis showed that the base results were greatly affected by the dosage of rhTPO and Etrapopa during maintainance period. In most cases ，rhTPO was economical. Probability sensitivity analysis showed that when willingness-to-pay threshold varied between 0 yuan and 250 000 yuan，the probability about that rhTPO was economical ranges from 99.90％ to 100％. CONCLUSIONS Based on the available evidence ，rhTPO is more economical in the short term than Etrapopa in the second-line treatment of ITP.

The mechanism research on Fuzheng Jiedu Decoction in the treatment of children with primary immune thrombocytopenia based on network pharmacology / 国际中医中药杂志

Objective:To explore the potential mechanism of Fuzheng Jiedu Decoction created by professor Yu Huiping in the treatment of primary immune thrombocytopenia (ITP) in children based on network pharmacology.Methods:The targets of Fuzheng Jiedu Decoction and ITP were retrieved within SymMap database and TCMID database, and all the common genes in the potential targets of the decoction and ITP were retained. The interaction relationship among the targets was obtained in the String database, and cluster analysis was conducted to obtain the core target group of Fuzheng Jiedu Decoction for ITP. In the David database, the potential KEGG Pathway was obtained through enrichment analysis, the Pathway of non-specific diseases was classified and selected, and a network of "Traditional Chinese Medicine - Target - Pathway" was constructed.Results:There are 500 potential targets for Fuzheng Jiedu Decoction to treat ITP. After Cluster analysis of PPI network, a total of 16 gene clusters were obtained, among which Cluster 1 score was 65.663, making it a potential core target group for Fuzheng Jiedu Decoction to treat ITP. The core enriched target group amounts to 114 pathways, and there were four first-level catalogs which includes Human Diseases (50%), Organismal Systems (25%), Environmental Information Processing (17%), and Cellular Processes (8%). Among them, TNF signaling pathway and HIF-1 signaling pathway were highly enriched for non-specific diseases. In the nodes of the network, The Chinese herbs with the highest Degree of aggregation in the network nodes were Agrimoniae herba (Degree=66), Glycyrrhizae radix et rhizoma praeparata cum melle (Degree=64), the target proteins were MAPK3 (Degree=51),MAPK1 (Degree=50),and the pathway was PI3K-Akt signaling pathway (Degree=29). Conclusion:Fuzheng Jiedu Decoction is mainly used to treat children's ITP with Agrimoniae herba and Glycyrrhizae radix et rhizoma praeparata cum melle,and it is related to the regulation of platelet number, adhesion and focusing.

A Case Report of Cyclic Thrombocytopenia with Periodic Anemia / 罕见病研究

Cyclic thrombocytopenia (CTP) is a rare hemorrhagic disorder characterized by cutaneous and mucosal bleeding and periodic fluctuations platelet count. The clinical characteristics and treatment response of a patient with CTP were analyzed. The patient is a 30-year-old male with recurrent cutaneous and mucosal bleeding for 5 years. Skin petechiae, oral blood blister, conjunctival hemorrhage, by tracing the history, monitoring changes in blood routine diagnosis of CTP, further testing of reticulocyte platelets and platelet hormone, and periodically promoting bone marrow megakaryocyte with changes of platelet, confirmed that the patient's periodic reduction in bone marrow hematopoiesis, was causing more damage. Periodic changes of reticulocyte, erythropoietin and erythroid hematopoiesis in bone marrow were also observed. The patient had normal Treg levels, no significant telomere length shortening in peripheral blood nucleated cells, and no clear pathogenic gene mutation was found by whole exon gene sequencing. Recombinant human thrombopoietin(rhTPO) treatment shortened the time of thrombocytopenia and increased the minimum platelet value. The average age of onset of CTP was 35 years old, some patients had severe bleeding, and more than half of the patients were misdiagnosed as primary immune thrombocytopenia. At present, the pathogenesis of CTP has not been clarified and there is no effective treatment. The experience of this patient suggests that rhTPO may be effective. This case of CTP complicated with periodic anemia is the first report. The exploration of its pathogenesis provides important information for understanding CTP.

Manifestaciones orales en pacientes con Trombocitopenia inmune primaria. Reporte de caso / Oral manifestations in primary immune thrombocytopenia patients. Case report

Resumen Introducción: La trombocitopenia inmune primaria (PTI) es una enfermedad caracterizada por la destrucción acelerada de plaquetas o la producción inadecuada de estas. Se puede clasificar según su etiología en primaria y secundaria. Métodos: Se presenta el caso de un paciente sexo masculino de 30 años de edad, que acude al servicio de urgencia dental del Hospital Barros Luco, por lesiones hemorrágicas mucosa oral y pequeñas manchas rojas en manos, brazos y espalda, de veinticuatro horas de evolución, asintomáticas y sin causa atribuible. Al examen físico se corrobora la presencia de múltiples vesículas hemorrágicas en región bucal y petequias en las zonas descritas. Se realiza diagnóstico presuntivo de PTI que se confirma al obtener un recuento plaquetario (RP) de 2000 uL. Se deriva a medicina interna para evaluación y manejo. La literatura describe que para confirmar esta enfermedad se requiere una historia clínica exhaustiva, descartar una patología sistémica o infecciosa previa y pruebas de laboratorio que evidencien recuento normal de células sanguíneas con una trombocitopenia marcada. Conclusión: El odontólogo tiene un rol significativo en el manejo multidisciplinario en este tipo de cuadros donde el conocimiento de manifestaciones orales de enfermedades sistémicas es de vital importancia para el diagnóstico, derivación y posterior tratamiento de estas.

Abstract Introduction: Primary immune thrombocytopenia (ITP) is a disease characterized by accelerated destruction of platelets or inadequate production of platelets. It can be classified according to its etiology in primary and secondary. Methods: We present the case of a 30-year-old male patient, who comes to the dental emergency service of the Barros Luco Hospital, for oral mucosa hemorrhagic lesions and small red spots on the hands, arms and back, 24 hours of evolution, asymptomatic and without attributable cause. Physical examination corroborates the presence of multiple hemorrhagic vesicles in the oral region and petechiae in the areas described. A presumptive diagnosis of ITP is made and confirmed by obtaining a platelet count (RP) of 2000 uL. He is referred to internal medicine for evaluation and management. The literature describes that confirming this disease requires an exhaustive medical history, ruling out a previous infectious or systemic pathology, and laboratory tests that show normal blood cell counts with marked thrombocytopenia. Conclusions: The dentist has a significant role in multidisciplinary management in this type of condition, where knowledge of oral manifestations of systemic diseases is of vital importance for the diagnosis, referral and subsequent treatment of these. Oral manifestations in primary immune thrombocytopenia patients. Case report

The incidence and risk factors for thrombosis in primary immune thrombocytopenia / 中华血液学杂志

Objective@#To probe the incidence and risk factors for thrombosis in Chinese immune thrombocytopenia through a retrospective analysis of the inpatients referred to the Blood Disease Hospital, CAMS & PUMC.@*Methods@#A retrospective survey of 3 225 patients with ITP from October 2005 to December 2017 was performed, the clinical data of the patients with thrombosis were collected to analyze the causes, diagnosis, treatment and prognosis.@*Results@#A total of 46 patients experienced a thrombotic event with a prevalence of 1.43%(46/3 225 cases) with the median age of thrombosis as 54 years (26-83) years, the prevalence of thrombosis was 3.37% (40/1 187 cases) in>40 years old, which was significantly higher than 0.58% (6/1 030 cases) in those under 40 years old, in adults (P=0.00). There were 20 males and 26 females, there was no statistical difference in the incidence of thrombosis between males and females[1.53% (20/1 309) vs 1.36% (26/1 916), P=0.187]; The prevalence of arterial thrombosis was 1.12% (36/3 225) higher than venous thrombosis[0.22% (7/3 225), P=0.00]when 82.61%(38/46 cases) of patients with PLT<100×109/L. Post-splenectomy are risk factors for thrombosis in ITP patients, P values was 0.022, There was no statistical difference in the presence or absence of thrombotic events whether received glucocorticoid or TPO/TPO-Ra treatment, the P values were 0.075 and 0.531, respectively.@*Conclusions@#In Chinese population, ITP disease maybe with a higher risk of thrombosis, there was no positive correlation between thrombosis and platelet level; and had obvious age distribution characteristics. The history of tobacco, hypertension, diabetes and post-splenectomy are risk factors for thrombosis in ITP patients.

Evolución de un cuadro de hemorragia intracraneal en lactante con trombocitopenia inmune primaria / Evolution of a case of intracraneal hemorrhage in infant with primary immune trombocytopenia

La trombocitopenia inmune primaria (TIP) es una enfermedad hematológica de causa inmunológica que presenta una plaquetopenia inferior a 100 000 plaquetas/mm3 y tiene una incidencia de 4 casos por cada 100 000 habitantes, siendo más prevalente entre los 2 a 6 años de edad. Esta entidad continúa siendo un desafío con respecto a la terapéutica y puede conllevar a complicaciones graves muy difíciles de resolver una vez establecidas.Se presenta el caso de un lactante menor de sexo masculino que curso con por un cuadro de palidez generalizada con aparición súbita de hematoma en mucosa oral, máculas equimóticas y hemorragias puntiformes en toda la superficie corporal. En los exámenes realizados se evidenciaron trombocitopenia y anemia grave, llegando al diagnóstico de trombocitopenia inmune primaria inicialmente manejada con transfusiones y posteriormente con corticoides. A pesar del manejo, el cuadro evolucionó con complicaciones de hemorragia intraparenquimatosa y declino neurológico.

Primary immune thrombocytopenia (PIT) is a hematological disease of immunological cause that has platelet count less than 100 000 platelets / mm3 and has an incidence of 4 cases per 100 000 inhabitants, being more prevalent between 2 and 6 years of age. This entity remains a challenge with regard to therapeutics and can lead to serious complications that are difficult to resolve once established. We report the case of a young male infant who has a generalized pallor with sudden onset of hematoma in the oral mucosa, equimotic macules and punctate hemorrhages throughout the body surface. In the examinations performed thrombocytopenia and severe anemia were evident, arriving at the diagnoses of idiopathic thrombocytopenic purpura initially managed with transfusions and later with corticoids. despite the treatment the case progress whith complications of intraparenchymal hemorrhage accompanied by neurological decline

Interleukin-1B (IL-1B-31 and IL-1B-511) and interleukin-1 receptor antagonist (IL-1Ra) gene polymorphisms in primary immune thrombocytopenia

BACKGROUND: Immune thrombocytopenia (ITP) is an immune-mediated disease caused by autoantibodies against platelets membrane glycoproteins GPIIb/IIIa and GPIb/IX. The etiology of ITP remains unclear. This study evaluated the association of polymorphisms in interleukin (IL)-1B-31, IL-1B-511, and IL-1Ra with ITP. METHODS: Genotyping of IL-1B-31, IL-1B-511, and IL-1Ra was performed in 118 ITP patients and 100 controls by polymerase chain reaction restriction fragment length polymorphism and detection of variable number tandem repeats. RESULTS: Genotype differences in IL-1B-31 and IL-1Ra were significantly associated with ITP. Patients showed a higher frequency of the IL-1B-31 variant allele (T) and a 1.52-fold greater risk of susceptibility to ITP (odds ratio [OR]=1.52, 95% confidence interval [CI]=1.04–2.22, P=0.034). The frequencies of both homozygous and heterozygous variant genotypes of IL-1B-31 were higher (OR=2.33, 95% CI=1.069–5.09, P=0.033 and OR=2.044, 95% CI=1.068–39, P=0.034) among patients and were significantly associated with ITP susceptibility. Both homozygous and heterozygous variant genotypes of IL-1Ra were also more frequent (OR=4.48, 95% CI=1.17–17.05, P=0.0230 and OR=1.80, 95% CI=1.03–3.14, P=0.0494) among patients and were associated with ITP risk. IL-1B-31 and IL-1Ra also showed significant association with severe ITP. However, IL-1B-511 was not associated with ITP. CONCLUSION: IL-1B-31 and IL-1Ra polymorphisms may significantly impact ITP risk, and they could be associated with disease severity, which may contribute to the pathogenesis of ITP.

Manifestaciones orales en pacientes con Trombocitopenia inmune primaria.Reporte de caso

Introducción: La trombocitopenia inmune primaria (PTI) es una enfermedad caracterizada por la destrucción acelerada de plaquetas o la producción inadecuada de estas. Se puede clasificar según su etiología en primaria y secundaria. Métodos: Se presenta el caso de un paciente sexo masculino de 30 años de edad, que acude al servicio de urgencia dental del Hospital Barros Luco, por lesiones hemorrágicas mucosa oral y pequeñas manchas rojas en manos, brazos y espalda, de veinticuatro horas de evolución, asintomáticas y sin causa atribuible. Al examen físico se corrobora la presencia de múltiples vesículas hemorrágicas en región bucal y petequias en las zonas descritas. Se realiza diagnóstico presuntivo de PTI que se confirma al obtener un recuento plaquetario (RP) de 2000 uL. Se deriva a medicina interna para evaluación y manejo. La literatura describe que para confirmar esta enfermedad se requiere una historia clínica exhaustiva, descartar una patología sistémica o infecciosa previa y pruebas de laboratorio que evidencien recuento normal de células sanguíneas con una trombocitopenia marcada. Conclusión: El odontólogo tiene un rol significativo en el manejo multidisciplinario en este tipo de cuadros donde el conocimiento de manifestaciones orales de enfermedades sistémicas es de vital importancia para el diagnóstico, derivación y posterior tratamiento de estas.

Introduction: Primary immune thrombocytopenia (ITP) is a disease characterized by accelerated destruction of platelets or inadequate production of platelets. It can be classified according to its etiology in primary and secondary. Methods: We present the case of a 30-year-old male patient, who comes to the dental emergency service of the Barros Luco Hospital, for oral mucosa hemorrhagic lesions and small red spots on the hands, arms and back, 24 hours of evolution, asymptomatic and without attributable cause. Physical examination corroborates the presence of multiple hemorrhagic vesicles in the oral region and petechiae in the areas described. A presumptive diagnosis of ITP is made and confirmed by obtaining a platelet count (RP) of 2000 uL. He is referred to internal medicine for evaluation and management. The literature describes that confirming this disease requires an exhaustive medical history, ruling out a previous infectious or systemic pathology, and laboratory tests that show normal blood cell counts with marked thrombocytopenia. Conclusions: The dentist has a significant role in multidisciplinary management in this type of condition, where knowledge of oral manifestations of systemic diseases is of vital importance for the diagnosis, referral and subsequent treatment of these. Oral manifestations in primary immune thrombocytopenia patients. Case report

Changes and mechanisms of Th9, Th17 and CD4+CD25+Foxp3+ regulatory T cells in the develop-ment of adult primary immune thrombocytopenia / 中华微生物学和免疫学杂志

Objective To investigate the expression and significance of Th9, Th17 and CD4+CD25+Foxp3+regulatory T (Treg) cells as well as the related cytokines (IL-9, IL-17, TGF-β) in peripheral blood of patients with adult primary immune thrombocytopenia ( ITP) . Methods Peripheral blood samples were collected from 47 patients with ITP and 39 age-and sex-matched healthy subjects. The percentages of Th9, Th17 and CD4+CD25+Foxp3+Treg cells in peripheral blood samples were detected with flow cytometry. The levels of IL-9, IL-17 and TGF-βin serum samples were detected by enzyme linked immunosorbent assay ( ELISA) . Results Compared with healthy subjects, the percentages of Th9 and Thl7 cells and the concen-trations of IL-9 and IL-17 in patients with ITP were significantly increased [(1. 27±0. 31)% vs (0. 71± 0. 26)%, P<0. 05;(2. 01±0. 42)% vs (0. 97±0. 32)%, P<0. 05. (26. 52±7. 48) ng/L vs (16. 16± 5. 27) ng/L, P<0. 05;(10. 97±3. 94) ng/L vs (7. 14±2. 73) ng/L, P<0. 05]. The percentages of CD4+CD25+Foxp3+ Treg cells and the concentrations of TGF-β in patients with ITP were lower than those in healthy subjects [(4. 69±0. 85)% vs (7. 16±1. 92)%, P<0. 05. (3. 76±1. 28) μg/L vs (6. 41±1. 83)μg/L, P<0. 05]. Moreover, the blood platelet counts in patients with ITP were negatively correlated with the percentages of Th9 and Th17 cells and the concentrations of IL-9 and IL-17 (γs=-0. 349, P=0. 037;γs=-0. 392, P=0. 031;γs=-0. 436, P=0. 014;γs=-0. 401, P=0. 027), but were positively correlated with the percentages of CD4+CD25+Foxp3+ Treg cells and the concentrations of TGF-β (γs=0. 411, P=0. 024;γs=0. 407, P=0. 026). Conclusion The imbalanced distribution of Th9, Th17 and Treg cells and the abnormal expression of related cytokines (IL-9, IL-17 and TGF-β) in patients with ITP might be the possible immunological pathogenesis of ITP.

A study on platelet indices and platelet membrane glycoprotein in children with primary immune thrombocytope-nia / 临床儿科杂志

ObjectiveTo investigate the change of the platelet function in children with primary immune thrombocy-topenia (ITP) before and after treatment.MethodsThe platelet indices, immature platelet fraction (IPF%), immature platelet counts (IPC), granule membrane glycoproteins of platelet (CD62p, PAC-1, CD42b) were tested by automatic blood cell analyzer and lfow cytometry (FCM) in 18 children with ITP before treatment and after complete response and in 17 children undergoing elective surgery (control gourp).ResultsCompared with control group, MPV, PDW, P-LCR and IPF% were signiifcantly higher and PLT, PCT, IPC were signiifcantly lower in children with ITP. The expressions of three platelet membrane glycoproteins (PAC-1, CD62p, CD42b) were signiifcantly lower in children with ITP. After treatment, children with ITP achieved completely response. Compared with before treatment, MPV, PDW, P-LCR and IPF% were signiifcantly lower, and PLT, PCT, IPC, and the expressions of three platelet membrane glycoproteins (PAC-1, CD62p and CD42b) were significantly higher. ConclusionsThe platelet function is depressed and in status of low activity in children with ITP. The relative platelet indices provide new references for the diagnosis and the judgment of therapeutic effect in ITP patients.

A clinical analysis of Weixuening granule combined with prednisone for treatment of patients with primary immune thrombocytopenia / 中国中西医结合急救杂志

Objective To observe the clinical efficacy of Weixuening granule combined with prednisone for treatment of patients with primary immune thrombocytopenia (ITP) and its impact on platelet-associated antibodies(PAIgG, PAIgM, PAIgA). Methods Sixty patients with ITP were randomly divided into a observation group (30 cases, Weixuening granule combined with prednisone) and a control group (30 cases, prednisone therapy alone), 3 months constituting a therapeutic course. The clinical effects, platelet count (PLT) and PAIgG, PAIgM, PAIgA of two groups were observed after two courses of treatment. The time of withdrawing prednisone, relapse rate in 1 year and adverse reactions were also monitored. Results The total effective rate of the observation group was higher than that of the control group [90.00%(27/30) vs. 73.33%(22/30), P0.05). Conclusions The combined use of Weixuening granule and prednisone for treatment of patients with primary ITP is more effective than administration of prednisone alone;the adverse reactions are less in combined therapy group. Possibly, the better therapeutic effect of combined therapy is related to the decrease of platelet-associated antibodies and increase of the platelet generation.

Th9 cells in peripheral blood of adult patients with primary immune thrombocytopenia and its clinical significance / 第二军医大学学报

Objective To observe Th9 cells and IL-9 level in adult patients with primary immune thrombocytopenia (ITP), and to discuss their potential roles in the pathogenesis of ITP. Methods A total of 25 newly diagnosed ITP patients and 25 sex- and age-matched healthy controls were enrolled in the present study. The percentage of Th9 cells in the peripheral blood samples of the two groups were detected by flow cytometry, expressions of IL-9, TGF-ß, PU. 1 and IRF4 mRNA were analyzed by real time-RCR, and IL-9 protein level was examined by ELISA. The platelet count was recorded by sysmex XE-2100. Results Compared with the healthy controls, the ratio of Th9 cells was significantly increased in ITP patients(P30×109/L(P30 × 109/L(P<0.05). Compared with healthy controls, the mRNA expressions of IL-9, TGF-ß, PU.1 and IRF4 were raised significantly in ITP patients(P<0.05). The ratio of Th9 cells and IL-9 protein level were negatively correlated with PLT in ITP patients(r= -0.428 1, P = 0.032 8; r= -0.537 5, P = 0.005 6, respectively). Furthermore, follow-up study of 11 ITP patients found that both Th9 cells and IL-9 protein levels took a declining tendency after effective treatment(P<0.05). Conclusion Abnormal activation of Th9/IL-9 may participate in the occurrence and development of ITP disease, which provides new clues for further understanding of ITP pathogenesis and selecting potential therapeutic targets in immune therapy of ITP.

Increased TRAIL Expression in Peripheral Blood Mononuclear Cells from Patients with Primary Immune Thrombocytopenia and Its Clinical Significance / 现代检验医学杂志

Objective To explore TRAIL expression in patients with primary immune thrombocytopenia (ITP)and its role in the pathogenesis.Methods Peripheral Blood Mononuclear Cells (PBMCs)from twenty-eight patients with ITP and thirty healthy controls were obtained.TRAIL expression was determined using Real-time Quantitative Polymerase Chain Reaction (RT-PCR).Serum TNF-α,IFN-γ,IL-4 and IL-10 were detected using ELISA.Associations between TRAIL expression and clinical parameters were assessed.Results Compared to healthy controls,TRAIL expression was significantly increased in PBMC from patients with ITP (2.80±0.43 vs 1.00±0.24,t=19.72,P0.05).Furthermore,TRAIL expression was positively correlated with serum IFN-γ,TNF-αlevel (r=0.432,0.541,P<0.05),and negatively correlated with IL-10 and PLT (r=-0.424,-0.553,P<0.05).Conclusion Rur results suggest that TRAIL may be involved in the pathogenesis of ITP.

Initial therapy indications of acute primary immune thrombocytopenia in children / 中华实用儿科临床杂志

Objective To explore the initial therapy indications of acute immune thrombocytopenia (ITP) in children based on the classification treatment.Methods Three hundred and eighty newly diagnosed ITP cases were enrolled in this study from Jan.1st 2012 to Apr.30th 2013 in Children's Hospital Affiliated to Shanghai Jiaotong University.In total 380 patients,there were 214 male cases (56.31％) and 166 female cases (43.68％).The cases were divided into observation group and therapy group according to the initial platelet count which was ≤ 30 × 109/L or the bleeding over moderate volume or with active bleeding.Platelet values were observed in the observation group weekly,adrenal cortical hormone and immunoglobulin treatment were adopted in the therapy group,cases were followed up to Aug.30th 2013,9 months on the average.Results Three hundred and five cases showed overall response (80.26％) and 75 cases showed no response(19.74％).One hundred and seventy-eight cases were divided into observation group (46.84％),in which 133 cases (74.72％) showed complete response or response.Two hundred and two cases were included in therapy group (53.16％),in which 167 cases (82.67％) were with complete response or response.There was no statistical difference between the 2 groups in curative effect (Z =-0.54,P =0.59).Forty-five cases in observation group were no response and accepted therapy,35 of them (77.78％) had response.There were equal efficiency in the initial therapy group and the subsequent therapy group (x2 =3.60,P =0.06).There was no difference between the age of onset,sex and season in 2 groups.Cases aged from 1 month to 1 year seemed to have a high incidence because of vaccination,and in the cases aged from 3 to 14 years the onset was related to infection.The children over 3 years old had higher risk factors in self-healing and the curative effect.There was no severe bleeding or adverse effect or dead cases in this study.Conclusions It is feasible to take platelet count ≤30 × 109/L as the threshold for initial therapy indications.Almost half of the cases could avoid overtreatment and pretherapy observation will not reduce the initial cure effect; no severe internal bleeding was observed in all the cases.

Trombocitopenia inmune primaria refractaria: opciones terapéuticas / Refractory primary immune thrombocytopenia: treatment options

La trombocitopenia inmune primaria (PTI) es un trastorno autoinmune adquirido caracterizado por una disminución transitoria o persistente del recuento de plaquetas con riesgo incrementado de sangramiento. La forma crónica de la enfermedad afecta fundamentalmente a los adultos. Puesto que las remisiones espontáneas son muy poco frecuentes, los pacientes son tratados desde el inicio, usualmente con esteroides. Aproximadamente un tercio de los casos no responden a los regímenes esteroideos y el tratamiento de segunda línea es la esplenectomía, tratamiento con el que se logran las mayores tasas de curación. Sin embargo, entre el 10 y el 30 por ciento de los pacientes no responden a la exéresis quirúrgica del bazo, que constituyen el grupo de pacientes con PTI crónica refractarios al tratamiento. No existen evidencias sobre cuál esquema terapéutico es el más efectivo en estos casos, por lo que el tratamiento continúa siendo empírico. En este trabajo se revisan las diferentes opciones terapéuticas que pueden ser utilizadas en la PTI crónica refractaria, el mecanismo de acción de las drogas, las dosis y los efectos adversos más frecuentes

The primary immune thrombocytopenia (PIT) is an acquired autoimmune disorder characterized by transient or persistent decreased platelet count with increased risk of bleeding. The chronic form of this disease primarily affects adults. Since spontaneous remissions are rare, patients usually are treated with steroids from the start. Approximately one third of the cases does not respond to steroid regimens; the second-line treatment is splenectomy, achieving the highest cure rates. However, between 10 to 30 percent of patients do not respond to spleen surgical removal, which is the group of patients with refractory chronic PIT. There is no evidence on whether this therapeutic regimen is most effective in these cases, so the treatment remains empirical. In this paper, various treatment options that can be used in refractory chronic PIT, the action mechanism of drugs, doses and more frequent adverse effects were reviewed